MedPage Today1 小时
High Price of GLP-1 Agents Tip Cost-Benefit Scale Unfavorably
Tirzepatide and semaglutide were associated with larger QALY gains (incremental gains of 0.35 and 0.25 over lifestyle ...
Healio2 小时
Semaglutide, tirzepatide not deemed cost-effective obesity therapies despite benefits
Semaglutide and tirzepatide confer greater improvements in life expectancy than naltrexone/bupropion and ...